We suggest a new, easily applicable way of myocardial hypertrophy induction in rats. Forty randomized age-matched male Wistar rats were divided into 2 groups of 20 each: a control group and an orally administered fludrocortisone/salt group. Myocardial hypertrophy was estimated by measuring body weight, heart-weight-to-body-weight ratio and ventricular free wall thickness. Moderate myocardial hypertrophy without heart failure was established in fludrocortisone/salt group in 4 weeks. Our method is effective and low cost, and it provides a model of hypertrophic heart.
SwynghedauwB. Molecular mechanisms of myocardial remodeling. Physiol Rev. 1999;79(1):215–262.
2.
TaylorPBTangQ. Development of isoproterenol-induced cardiac hypertrophy. Can J Physiol Pharmacol. 1984;62(4):384–389.
3.
TaylorQTaylorPBHelbingRK. Catecholamine induced hypertrophy. Can J Cardiol. 1987;3(6):311–316.
4.
HasenfussG. Animal models of human cardiovascular disease, heart failure and hypertrophy. Cardiovasc Res. 1998;39(1):60–76.
5.
BregagnolloEARodriguesMAMMontenegroMRCuriPRTucciPJ. Temporal evolution of structural and functional parameters of cardiac hypertrophy induced in Wistar rats by abdominal aorta constriction. Arq Bras Cardiol. 1986;46(1):9–17.
6.
BingOHLMatsushitaSFanburgBLLevineHJ. Mechanical properties of rat cardiac muscle during experimental hypertrophy. Circ.
Res. 1971;28(2):234–245.
7.
SchlensakCSaraiKGildenHPBeyersdorfF. Pulmonary banding with a novel percutaneously, bidirectionally adjustable device. Eur J Cardiothorac Surg. 1997;12(6):931–933.
8.
TrippodoNCFrohlichED. Similarities of genetic (spontaneous) hypertension. Man and rat. Circ Res. 1981;48(3):309–319.
9.
DoggrellSABrownL. Rat models of hypertension, cardiac hypertrophy and failure. Cardiovasc Res. 1998;39(1):89–105.
10.
FolkowBHallbackMPhysiopathology of spontaneous hypertension in rats. In: GenestJKoiwEKuchelO (Eds.), Hypertension Physiopathology and Treatment.1977;New York, NY: McGraw-Hill, 507–529.
11.
MartinsASAguileraNWMatsubaraBBBregagnolloEA. Experimental myocardial hypertrophy induced by a minimally invasive ascending aorta coarctation. Bra J Med Biol Res. 2001;34:413–415.
12.
BaxterGFYellonDM. Regression of left ventricular hypertrophy and susceptibility to reperfusion-induced arrhythmias after DOCA-salt hypertension in the rat. Cardioscience. 1992;3(4):245–250.
YoshidaKKim-MitsuyamaSWakeR. Excess aldosterone under normal salt diet induces cardiac hypertrophy and infiltration via oxidative stress. Hypertens Res. 2005;28(5):447–455.
15.
BlankSDLahorraJAMcDonaldRS. Superior recovery of hypertrophied rat myocardium after cardioplegic arrest. Ann Thorac Surg. 1998;65(2):390–396.
16.
RaynerB. Primary aldosteronism and aldosterone-associated hypertension. J Clin Pathol. 2008;61(7):825–831.
17.
OkiKYamaneK. Therapies for adrenal insufficiency. Expert Opin Pharmacother. 2007;8(9):1283–1291.
18.
HahnerSAllolioB. Management of adrenal insufficiency in different clinical settings. Expert Opin Pharmacother. 2005;6(14):2407–2417.
19.
FreemanR. Current pharmacologic treatment for orthostatic hypotension. Clin Auton Res. 2008;18(suppl 1):14–18.
20.
GenardPPalem-VliersM. Effect of 6-dehydro-DOCA and 6-dehydro-9 alpha-fluorocortisol acetate on the excretion of sodium and potassium in the rat. J Steroid Biochem. 1985;23(5A):673–675.
Callens-el AmraniFSnoeckxL. Anoxia-induced changes in ventricular diastolic compliance in two models of hypertension in rats. J Hypertens. 1992;10(3):229–236.
26.
FribergPFolkowBNordlanderM. Structural adaptation of the rat left ventricle in response to changes in pressure and volume loads. Acta Physiol Scand. 1985;125(1):67–79.
27.
HartG. Cellular electrophysiology in cardiac hypertrophy and failure. Cardiovasc Res. 1994;28(7):933–946.
